Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
3.630
-0.450 (-11.01%)
Nov 21, 2024, 11:54 AM EST - Market open
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $11.61M in the quarter ending September 30, 2024, with 8.15% growth. This brings the company's revenue in the last twelve months to $43.38M, up 15.67% year-over-year. In the year 2023, Tango Therapeutics had annual revenue of $36.53M with 46.93% growth.
Revenue (ttm)
$43.38M
Revenue Growth
+15.67%
P/S Ratio
10.14
Revenue / Employee
$309,879
Employees
140
Market Cap
389.93M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
Dec 31, 2019 | 24.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Health Catalyst | 302.06M |
Sonida Senior Living | 253.20M |
SIGA Technologies | 173.73M |
Arcturus Therapeutics Holdings | 160.40M |
National Research | 144.16M |
Aquestive Therapeutics | 58.90M |
Foghorn Therapeutics | 25.52M |
TNGX News
- 15 days ago - Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 15 days ago - Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program - Business Wire
- 2 months ago - Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data - Seeking Alpha
- 3 months ago - Tango Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights - Business Wire
- 6 months ago - Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 6 months ago - Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program - PRNewsWire
- 6 months ago - Tango Therapeutics to stop development of cancer therapy - Reuters